Sign in

You're signed outSign in or to get full access.

Jingming Chen

Jingming Chen

Research Analyst at Evercore ISI

Chicago, IL, US

Jingming Chen is an Equity Research Analyst at Evercore ISI focused on biotechnology, frequently engaging in research and earnings calls for companies such as Travere Therapeutics and Innate Pharma. Chen contributes research coverage and analysis for clinical-stage biopharmaceutical firms, providing market insights and forecasts for investors and clients. While performance metrics such as TipRanks rankings or success rates are not publicly available, Chen has participated in key sector earnings calls and research commentary since at least early 2023. Chen holds a research analyst role and specializes in biotechnology and pharmaceutical company coverage, though specific professional credentials and securities licenses are not disclosed in publicly available sources.

Jingming Chen's questions to Editas Medicine (EDIT) leadership

Question · Q2 2024

Jingming Chen, on for Liisa Bayko, asked how Editas plans to target the large patient population in the Middle East, questioning if they would launch themselves or seek a partner.

Answer

Chief Commercial and Strategy Officer Caren Deardorf acknowledged the significant unmet need in the Middle East and other geographies. She reiterated the company's strategy to 'consider partnering for anything outside of the United States' to accelerate patient access to therapies like reni-cel.

Ask follow-up questions

Fintool

Fintool can predict Editas Medicine logo EDIT's earnings beat/miss a week before the call

Jingming Chen's questions to Innate Pharma (IPHA) leadership

Question · Q2 2023

The analyst asked about the timing and venue for the upcoming lacutamab data release and the subsequent regulatory and development strategy for the drug in CTCL, including potential filing plans.

Answer

The company will present lacutamab data at a medical conference in H2 2023 once an abstract is accepted. The next steps involve discussions with the FDA to finalize Phase 3 plans based on the new data, while also actively exploring partnerships to maximize the asset's value and guide later-stage development.

Ask follow-up questions

Fintool

Fintool can predict Innate Pharma logo IPHA's earnings beat/miss a week before the call